Cite

    Urabe, F. et al. (2022). Clinical significance of unfavorable findings in intermediate‐risk prostate cancer patients for predicting treatment outcomes after contemporary, dose‐escalated multimodal radiotherapy. Prostate. 82 (4), pp. 433-441. [Online].